Skip to main content
. 2019 Nov 21;107(3):617–627. doi: 10.1002/cpt.1665

Table 2.

Phenotype frequencies and actionability

Gene Phenotype Number of subjects Frequency Actionable
CYP2B6 1,577
PM 105 6.7% Yes
IM 528 33.5% Yes
EM 944 59.9%
CYP2C19 15
PM   Yes
IM 4 26.7% Yes
EM 11 73.3%
UM Yes
CYP2C9   1,583
PM 59 3.7% Yes
IM 487 30.2% Yes
EM 1,037 65.5%
CYP2D6 1,576
PMa 66 4.2% Yes
Not assigned 1,510 95.8%
CYP3A5 1,163
PM 882 75.8%
IM 263 22.6% Yes
EM 18 1.5% Yes
DPYD 1,581
AS: 0 Yes
AS: 0.5 Yes
AS: 1 21 1.3% Yes
AS: 1.5 95 6.0% Yes
AS: 2 1,465 92.7%
F5L 1,583
F5 Absent 1,504 95.0%
F5 Heterozygous 78 4.9% Yes
F5 Homozygous 1 0.06% Yes
SLCO1B1 1,579
Normal function 1,172 74.2%  
Decreased function 371 23.5% Yes
Poor function 36 2.3% Yes
TPMT 1,562
PM 1 0.06% Yes
IM 139 8.9% Yes
EM 1,422 91.0%
VKORC1 1,549
Normal function (1173CC) 564 36.4%
Decreased function (1173CT) 723 46.7%
Poor function (1173TT) 262 16.9% Yes

Phenotypes are based on the Ubiquitous Pharmacogenomics consortium translation tables, actionability is based on the Dutch Pharmacogenetic Working Group guidelines, whereas actionable is defined as a phenotype accompanied by at least one dosing advise.

AS, Activity Score; EM, extensive metabolizer; F5, Factor V Leiden; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultra‐rapid metabolizer.

a

Poor metabolizer phenotype assigned based on diplotype consisting of two null‐alleles. For all other diplotypes no CYP2D6 phenotype could be assigned as copy number variants could not be determined.

HHS Vulnerability Disclosure